Katherine R. Schultz

发表

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

G. Getz, A. Iafrate, J. Engelman, 2016, The New England journal of medicine.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

S. Digumarthy, Y. Yagi, C. Azzoli, 2016, Clinical Cancer Research.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016, Cancer discovery.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016 .

Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).

C. Azzoli, M. Mino‐Kenudson, L. Sequist, 2015 .

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, A. Shaw, 2017, JCO precision oncology.

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

J. Engelman, A. Shaw, B. Yeap, 2015, Clinical Cancer Research.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Markus Riester, Cyril H Benes, S. Digumarthy, 2018, JCO precision oncology.

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

G. Getz, A. Iafrate, J. Engelman, 2016, The New England journal of medicine.